ResearcherInha UniversityActive in the last 2 years
Soo‐Youl Kim
Matched on ORCID iD 0000-0002-4021-2206; OpenAlex author ID A5014464546, A5110088296. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 17
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 6
- Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-25-4517↗
- Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Last author DOI 10.3390/cancers17182988↗
- Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet. Last author DOI 10.7150/thno.114912↗
- A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. Co-author DOI 10.1093/jnci/djab191↗
- Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. Last author DOI 10.7150/thno.53935↗
- ATP Production Relies on Fatty Acid Oxidation Rather than Glycolysis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers12092477↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sang Myung Woo · 5 shared papers, 2020–2026 · strength 0.90
- Paper Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adeno… DOI 10.1158/0008-5472.can-25-4517↗
- Paper Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. DOI 10.3390/cancers17182988↗
- Paper Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet. DOI 10.7150/thno.114912↗
- Jung Won Chun · 3 shared papers, 2025–2026 · strength 0.67
- Paper Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adeno… DOI 10.1158/0008-5472.can-25-4517↗
- Paper Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. DOI 10.3390/cancers17182988↗
- Paper Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet. DOI 10.7150/thno.114912↗
- Woo Jin Lee · 2 shared papers, 2025–2026 · strength 0.47
- Paper Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adeno… DOI 10.1158/0008-5472.can-25-4517↗
- Paper Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. DOI 10.3390/cancers17182988↗
- Hyonchol Jang · 3 shared papers, 2020–2026 · strength 0.46
- Paper Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adeno… DOI 10.1158/0008-5472.can-25-4517↗
- Paper Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. DOI 10.7150/thno.53935↗
- Paper ATP Production Relies on Fatty Acid Oxidation Rather than Glycolysis in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers12092477↗
- Sung‐Sik Han · 2 shared papers, 2021–2025 · strength 0.35
- Hyeong Min Park · 1 shared paper, 2025 · strength 0.23
- Sang‐Jae Park · 1 shared paper, 2025 · strength 0.23
- Kyung Hee Jung · 1 shared paper, 2022 · strength 0.13
- Woohyung Lee · 1 shared paper, 2022 · strength 0.13
- Sunghyouk Park · 1 shared paper, 2022 · strength 0.13
- Hoonsik Nam · 1 shared paper, 2022 · strength 0.13
- Soon‐Sun Hong · 1 shared paper, 2022 · strength 0.13
- Song Cheol Kim · 1 shared paper, 2022 · strength 0.13
- Jae-Seon Lee · 1 shared paper, 2021 · strength 0.12
- Eun Kyung Hong · 1 shared paper, 2021 · strength 0.12
- Jaekyoung Son · 1 shared paper, 2021 · strength 0.12
- Jae‐Seon Lee · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.